vs
Side-by-side financial comparison of NovaBay Pharmaceuticals, Inc. (NBY) and TOP Financial Group Ltd (TOP). Click either name above to swap in a different company.
NovaBay Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($4.8M vs $2.9M, roughly 1.7× TOP Financial Group Ltd). TOP Financial Group Ltd runs the higher net margin — 6.6% vs -25.5%, a 32.2% gap on every dollar of revenue.
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
Sun Life Financial Inc. is a Canadian financial services company headquartered in Toronto, Ontario. Founded in 1865, it operates internationally in life insurance, wealth management, and asset management. As of 2024, the company manages over CAD$1.3 trillion in assets and serves clients in Canada, the United States, Asia, and other markets.
NBY vs TOP — Head-to-Head
Income Statement — Q4 FY2024 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $2.9M |
| Net Profit | $-1.2M | $190.5K |
| Gross Margin | 65.2% | — |
| Operating Margin | -37.2% | — |
| Net Margin | -25.5% | 6.6% |
| Revenue YoY | 126.1% | — |
| Net Profit YoY | 70.5% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $2.9M | ||
| Q4 24 | $4.8M | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $2.4M | — | ||
| Q1 24 | $2.6M | — | ||
| Q4 23 | $2.1M | — | ||
| Q3 23 | $2.5M | — | ||
| Q2 23 | $3.5M | — |
| Q3 25 | — | $190.5K | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-3.2M | — | ||
| Q4 23 | $-4.1M | — | ||
| Q3 23 | $-1.8M | — | ||
| Q2 23 | $-2.0M | — |
| Q3 25 | — | — | ||
| Q4 24 | 65.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 66.3% | — | ||
| Q1 24 | 68.2% | — | ||
| Q4 23 | 51.5% | — | ||
| Q3 23 | 67.0% | — | ||
| Q2 23 | 49.2% | — |
| Q3 25 | — | — | ||
| Q4 24 | -37.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -67.4% | — | ||
| Q1 24 | -87.1% | — | ||
| Q4 23 | -48.0% | — | ||
| Q3 23 | -28.1% | — | ||
| Q2 23 | -29.7% | — |
| Q3 25 | — | 6.6% | ||
| Q4 24 | -25.5% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -66.0% | — | ||
| Q1 24 | -122.2% | — | ||
| Q4 23 | -195.5% | — | ||
| Q3 23 | -70.8% | — | ||
| Q2 23 | -57.6% | — |
| Q3 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.92 | — | ||
| Q2 24 | $-1.37 | — | ||
| Q1 24 | $-29.95 | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $430.0K | $14.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-129.0K | $35.0M |
| Total Assets | $3.4M | $64.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $14.8M | ||
| Q4 24 | $430.0K | — | ||
| Q3 24 | $776.0K | — | ||
| Q2 24 | $751.0K | — | ||
| Q1 24 | $1.8M | — | ||
| Q4 23 | $2.9M | — | ||
| Q3 23 | $3.5M | — | ||
| Q2 23 | $4.4M | — |
| Q3 25 | — | $35.0M | ||
| Q4 24 | $-129.0K | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $-617.0K | — | ||
| Q1 24 | $160.0K | — | ||
| Q4 23 | $3.3M | — | ||
| Q3 23 | $7.0M | — | ||
| Q2 23 | $8.6M | — |
| Q3 25 | — | $64.1M | ||
| Q4 24 | $3.4M | — | ||
| Q3 24 | $3.9M | — | ||
| Q2 24 | $3.9M | — | ||
| Q1 24 | $5.4M | — | ||
| Q4 23 | $9.0M | — | ||
| Q3 23 | $12.9M | — | ||
| Q2 23 | $16.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | — |
| Free Cash FlowOCF − Capex | $-1.7M | — |
| FCF MarginFCF / Revenue | -35.4% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | $-1.4M | — | ||
| Q1 24 | $-2.0M | — | ||
| Q4 23 | $-592.0K | — | ||
| Q3 23 | $-646.0K | — | ||
| Q2 23 | $-1.7M | — |
| Q3 25 | — | — | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-2.0M | — | ||
| Q4 23 | $-595.0K | — | ||
| Q3 23 | $-647.0K | — | ||
| Q2 23 | $-1.7M | — |
| Q3 25 | — | — | ||
| Q4 24 | -35.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -75.3% | — | ||
| Q4 23 | -28.3% | — | ||
| Q3 23 | -26.1% | — | ||
| Q2 23 | -48.3% | — |
| Q3 25 | — | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.1% | — | ||
| Q4 23 | 0.1% | — | ||
| Q3 23 | 0.0% | — | ||
| Q2 23 | 0.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
TOP
Segment breakdown not available.
